Fulcrum Therapeutics, Inc. Stock News

Fulcrum Therapeutics (FULC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

CAMBRIDGE, Mass., June 24, 2020 -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with.

Foresite Capital Management IV LLC lessened its position in shares of Fulcrum Therapeutics (NASDAQ:FULC) by 33.4% during the 1st quarter, according to the company in its most recent disclosure with th

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Ev

Fulcrum Therapeutics, Inc. (FULC) today announced the closing of a $68.5 million private placement pursuant to a securities purchase agreement with a group of institutional investors and accredited i

Fulcrum Therapeutics, Inc. (FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced plans to evaluate losm

Fulcrum Therapeutics, Inc. (FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced multiple presentations

As of late, it has definitely been a great time to be an investor in Fulcrum Therapeutics, Inc. (FULC).

With me on today's call are Robert Gould, president and chief executive officer; Diego Cadavid, senior vice president of clinical development; Owen Wallace, chief scientific officer; and Bryan Stuart,

Fulcrum Therapeutics, Inc. (FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and r

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Acceleron Pharma Inc (NASDAQ...

CAMBRIDGE, Mass., May 11, 2020 -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with.

The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...

CAMBRIDGE, Mass., May 07, 2020 -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with.